Oral administration of creatine monohydrate retards progression of motor neuron disease in the wobbler mouse

Amyotrophic Lateral Sclerosis

Volumn 1, Issue 3, 2000, Pages 207-212

  Ikeda, Ken ^a   Iwasaki, Yasuo ^a   Kinoshita, Masao ^a  

^a TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

Author keywords

Creatine Monohydrate Wobbler Mouse Motor Neuron Disease

Indexed keywords

CREATINE;

ANIMAL; ARTICLE; CELL COUNT; DISEASE COURSE; DISEASE MODEL; FORELIMB; HAND GRIP; METABOLISM; MOTONEURON; MOTOR NEURON DISEASE; MOUSE; MOUSE MUTANT; ORAL DRUG ADMINISTRATION; ORGAN SIZE; PATHOLOGY; SKELETAL MUSCLE; SPINAL CORD;

ADMINISTRATION, ORAL; ANIMALS; CELL COUNT; CREATINE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FORELIMB; HAND STRENGTH; MICE; MICE, NEUROLOGIC MUTANTS; MOTOR NEURON DISEASE; MOTOR NEURONS; MUSCLE, SKELETAL; ORGAN SIZE; SPINAL CORD;

EID: 0034208612     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.1080/14660820050515205     Document Type: Article

References (22)

1. O'Gorman E, Beutner G, Wallimann T, Brdiczka D. Differential effects of creatine depletion on the regulation of enzyme activities and on creatine-stimulated mitochondrial respiration in skeletal muscle, heart, and brain. Biochem Biophys Acta 1996; 1276: 161-170. (Pubitemid 26308733)
2. Matthews RT, Yang L, Jenkins BG, et al. Neuroprotective effects of creatine and cyclocreatine in animal models in Huntington's disease. J Neurosci 1998; 18: 156-163. (Pubitemid 28046777)
3. Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyo-trophic lateral sclerosis. Nature Med 1999; 5: 347-350. (Pubitemid 29124375)
4. Tarnopolsky M, Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 1999; 52: 854-857. (Pubitemid 29120197)
5. Ikeda K, Klinkosz B, Greene T, et al. Effects of brain-derived neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease. Ann Neurol 1995; 37: 505-511.
6. Ikeda K, Kinoshita M, Iwasaki Y, Tagaya N, Shiojima T. Lecithinized superoxide dismutase retards wobbler mouse motoneuron disease. Neuromusc Disord 1995; 5: 383-390.
7. Ikeda K, Iwasaki Y, Tagaya N, Shiojima T, Kobayashi T, Kinoshita M. Neuroprotective effect of basic fibroblast growth factor on wobbler mouse motor neuron disease. Neurol Res 1995; 17: 445-448.
8. Ikeda K, Iwasaki Y, Tagaya N, Shiojima T, Kinoshita M. Neu-roprotective effect of cholinergic differentiation factor/leukemia inhibitory factor (CDF/LIF) on wobbler murine motor neuron disease. Muscle Nerve 1995; 18: 1344-1347.
9. Ikeda K, Kinoshita M, Tagaya N, et al. Coadministration of interleukin-6 (IL-6) and soluble IL-6 receptor delays progression of wobbler mouse motor neuron disease. Brain Res 1996; 726: 91-97. (Pubitemid 26292234)
10. Ikeda K, Iwasaki Y, Kinoshita M thyrotropin-releasing hormone analogue, protects against spinal motor neuron degeneration in the wobbler mouse. Neurosci Lett 1998; 250: 9-12. (Pubitemid 28341764)
11. Ikeda K, Iwasaki Y, Kinoshita M. Neuronal nitric oxide synthase inhibitor, 7-nitroindazole, delays motor dysfunction and spinal motoneuron degeneration in the wobbler mouse. J Neurol Sci 1998; 160: 9-15. (Pubitemid 28473879)
12. Mitsumoto H, Ikeda K, Holmlund TH, et al. The effect of ciliary neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease. Ann Neurol 1994; 36: 142-148. (Pubitemid 24239230)
13. Mitsumoto H, Ikeda K, Klinkosz B, Cedarbaum JM, Wong V, Lindsay RM. Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF. Science 1994; 265:1107-1110. (Pubitemid 24293081)
14. Ikeda K, Wong V, Holmlund TH, et al. Histometric effects of ciliary neurotrophic factor in wobbler mouse motor neuron disease. Ann Neurol 1995; 37: 47-54.
15. Duchen LW, Strich SJ. An hereditary motor neurone disease with progressive denervation of muscle in the mouse: the mutant 'wobbler'. J Neurol Neurosurg Psychiatry 1968; 31: 535-542.
16. Mitsumoto H, Bradley WG. The wobbler mouse: the murine motor neuron disease: degeneration and regeneration of the lower motor neuron. Brain 1982; 105: 811-834. (Pubitemid 13241013)
17. Wallimann T, Wyss M, Brdiczka D, Nicolay K, Eppenberger HM. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis. Biochem J 1992; 281: 21-40.
18. Guimbal C, Kilimann MW. A Na+-dependent creatine transporter in rabbit brain, muscle, heart and kidney. J Biol Chem 1993; 268: 8418-8421.
19. Hemmer W, Wallimann T. Functional aspects of creatine kinase in brain. Dev Neurosci 1993; 15: 246-260.
20. Tarnopolsky MA, Roy BD, MacDonald JR. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 1997; 20: 1502-1509. (Pubitemid 27512338)
21. Ikeda K, Kinoshita M, Iwasaki Y, Wakata N. Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 2000; 54: 537. (Pubitemid 30078114)
22. Sipilä I, Rapola J, Simell O, Vannas A. Supplementary creatine as a treatment for gyrate atrophy of the choroid and retina. N Engl J Med 1981; 304: 867-870. (Pubitemid 11101069)